Sifting through countless of stocks in the Health Care Providers & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Cencora, Inc. or DaVita Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Cencora, Inc. and DaVita Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Cencora, Inc. and DaVita Inc.

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Latest Health Care Providers & Services and Cencora, Inc., DaVita Inc. Stock News

As of July 31, 2026, Cencora, Inc. had a $60.6 billion market capitalization, compared to the Health Care Providers & Services median of $1.7 million. Cencora, Inc.’s stock is down 7.8% in 2026, up 0.5% in the previous five trading days and up 6.7% in the past year.

Currently, Cencora, Inc.’s price-earnings ratio is 23.9. Cencora, Inc.’s trailing 12-month revenue is $328.7 billion with a 0.8% net profit margin. Year-over-year quarterly sales growth most recently was 3.8%. Analysts expect adjusted earnings to reach $17.784 per share for the current fiscal year. Cencora, Inc. currently has a 0.8% dividend yield.

As of July 31, 2026, DaVita Inc. had a $15.4 billion market cap, putting it in the 83rd percentile of all stocks. DaVita Inc.’s stock is up 111.3% in 2026, up 2% in the previous five trading days and up 66.07% in the past year.

Currently, DaVita Inc.’s price-earnings ratio is 23.1. DaVita Inc.’s trailing 12-month revenue is $13.8 billion with a 5.6% net profit margin. Year-over-year quarterly sales growth most recently was 6.0%. Analysts expect adjusted earnings to reach $14.879 per share for the current fiscal year. DaVita Inc. does not currently pay a dividend.

How We Compare Cencora, Inc. and DaVita Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Cencora, Inc. and DaVita Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Cencora, Inc. and DaVita Inc.’s Quality Grades

Company	Ticker	Quality
Cencora, Inc.	COR	D
DaVita Inc.	DVA	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Cencora, Inc. has a Quality Score of 26, which is Weak. DaVita Inc. has a Quality Score of 86, which is Very Strong.

The Quality Grade Winner: DaVita Inc.

As you can clearly see from the Quality Grade breakdown above, DaVita Inc. has a better overall quality grade than Cencora, Inc.. For investors who are looking for companies with higher quality than others in the same industry, DaVita Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Cencora, Inc. and DaVita Inc.’s Momentum Grades

Company	Ticker	Momentum
Cencora, Inc.	COR	C
DaVita Inc.	DVA	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Cencora, Inc. has a Momentum Score of 48, which is Average. DaVita Inc. has a Momentum Score of 93, which is Very Strong.

The Momentum Grade Winner: DaVita Inc.

As you can clearly see from the Momentum Grade breakdown above, DaVita Inc. is considered to have stronger momentum compared to Cencora, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, DaVita Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Cencora, Inc. and DaVita Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Cencora, Inc.	COR	C
DaVita Inc.	DVA	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Cencora, Inc. has a Earnings Estimate Score of 46, which is Neutral. DaVita Inc. has a Earnings Estimate Score of 70, which is Positive.

The Earnings Estimate Revisions Grade Winner: DaVita Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, DaVita Inc. has a better Earnings Estimate Revisions Grade than Cencora, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, DaVita Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Cencora, Inc. and DaVita Inc. Grades

In addition to Momentum, Estimate Revisions and Quality, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Cencora, Inc. and DaVita Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Cencora, Inc. or DaVita Inc. Stock?

Overall, Cencora, Inc. stock has a Momentum Score of 48, Estimate Revisions Score of 46 and Quality Score of 26.

DaVita Inc. stock has a Momentum Score of 93, Estimate Revisions Score of 70 and Quality Score of 86.

Comparing Cencora, Inc. and DaVita Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.